5053-14-5

Basic information

• Product Name: 8-Benzyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one
• Synonyms: 8-Benzyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one
• CAS NO: 5053-14-5
• Molecular Formula: C₁₄H₁₈N₂O₂
• Molecular Weight: 246.31
• Mol File: 5053-14-5.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 457.1°Cat760mmHg
• Flash Point: 230.2°C
• Appearance: /
• Density: 1.22g/cm³
• Vapor Pressure: 1.54E-08mmHg at 25°C
• Refractive Index: 1.6
• CAS DataBase Reference: 8-Benzyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 8-Benzyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one(5053-14-5)
• EPA Substance Registry System: 8-Benzyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one(5053-14-5)

Safety Data

• Hazardous Substances Data: 5053-14-5(Hazardous Substances Data)

Usage

General Description

8-Benzyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one is a chemical compound with the molecular formula C16H21NO2. It is a spiro compound, meaning its structure includes a bicyclic ring system where one of the rings shares two adjacent carbon atoms with the other. 8-Benzyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one contains a benzyl group, an oxygen atom, and two nitrogen atoms within its structure. It has potential applications in the field of medicinal chemistry, where spiro compounds have been investigated for their diverse biological activities, including antimicrobial, anticancer, and central nervous system-modulating properties. Studies suggest that spiro compounds like 8-Benzyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one may hold promise for the development of new pharmaceutical agents.

InChI:InChI=1/C14H18N2O2/c17-13-15-11-14(18-13)6-8-16(9-7-14)10-12-4-2-1-3-5-12/h1-5H,6-11H2,(H,15,17)

Upstream product

• 67281-07-6 ethyl 2-(1-benzyl-4-hydroxypiperidin-4-yl)acetate 
• 177948-01-5 [[4-hydroxy-1-(phenylmethyl)-4-piperidinyl]methyl]carbamic acid 1,1-dimethylethyl ester 
• 23804-68-4 4-(aminomethyl)-1-benzyl-4-hydroxypiperidine 
• 530-62-1 1,1'-carbonyldiimidazole 
• 6094-60-6 1-benzyl-4-hydroxypiperidine-4-carbonitrile 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 77211-73-5 2-(1-benzyl-4-hydroxypiperidin-4-yl)acetyl hydrazine 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 105-58-8 Diethyl carbonate 
• 19867-34-6 N-benzyl-1-oxa-6-azaspiro[2,5]-octane 
• 156215-49-5 1-benzyl-4-(trimethylsilyloxy)piperidine-4-carbonitrile 

Downstream Products

• 77211-43-9 3-propyl-8-benzyl-1-oxa-3,8-diazaspiro<4.5>decan-2-one 
• 77211-46-2 8-(carbobenzyloxy)-1-oxa-3,8-diazaspiro<4.5>decan-2-one 
• 77211-47-3 3-methyl-8-(carbobenzyloxy)-1-oxa-3,8-diazaspiro<4.5>decan-2-one 
• 77211-59-7 8-[2-Hydroxy-3-(2-methoxy-phenoxy)-propyl]-1-oxa-3,8-diaza-spiro[4.5]decan-2-one 
• 77211-48-4 3-Benzyl-2-oxo-1-oxa-3,8-diaza-spiro[4.5]decane-8-carboxylic acid benzyl ester 
• 79053-53-5 3-methyl-8-[3-(2-methoxyphenoxy)-2-hydroxypropyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 
• 79053-04-6 (S)-3-methyl-8-<3-(2-methoxyphenoxy)-2-hydroxypropyl>-1-oxa-3,8-diazaspiro<4.5>decan-2-one 
• 79053-52-4 (R)-3-methyl-8-<3-(2-methoxyphenoxy)-2-hydroxypropyl>-1-oxa-3,8-diazaspiro<4.5>decan-2-one 
• 1463-48-5 8-benzyl-2,8-diaza-spiro[4.5]decane-1,3-dione 
• 1538608-34-2 N-(2-amino-5-(4-methylthiophen-2-yl)phenyl)-6-(2-oxo-1-oxa-3,8-diazaspiro[4.5]decan-8-yl)nicotinamide 
• 1538608-35-3 N-(4-amino-4'-fluoro-[1,1'-biphenyl]-3-yl)-6-(2-oxo-1-oxa-3,8-diazaspiro[4.5]decan-8-yl)nicotinamide 
• 1538608-36-4 N-(2-amino-5-(1-methyl-1H-pyrazol-4-yl)phenyl)-6-(2-oxo-1-oxa-3,8-diazaspiro[4.5]decan-8-yl)nicotinamide 
• 1538608-37-5 N-(2-amino-5-(1-methyl-1H-imidazol-4-yl)phenyl)-6-(2-oxo-1-oxa-3,8-diazaspiro[4.5]decan-8-yl)nicotinamide 

Relevant articles and documents

Oxazolidinone compounds and its use in medicine

The invention relates to novel oxazolidinone compounds or stereoisomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites and pharmaceutically-acceptable salts or prodrugs of the novel oxazolidinone compounds. The invention a

Spirocyclic derivatives

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease, disorder or condition ameliorated by inhibition of a dopamine transporter); and methods of treating patients with such compounds; wherein R1, R2, R3, R4, R5, R6, R9, R10, Q, X, Y, Z, A, L, B, m, n and p are as defined herein.

Inhibitors of prenyl-protein transferase

The present invention is directed to conformationally constrained compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.